Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on November 5, 2019, to announce the extension of the expiration date for its exchange offers and consent solicitations related to Celgene Corporation notes. These actions are in connection with BMY's pending acquisition of Celgene, which is expected to close by the end of 2019. The exchange offers allow holders of Celgene notes to tender them for new BMY notes and cash, while the consent solicitations aim to amend the terms of the Celgene notes. The primary takeaway for investors is that the timeline for the completion of the Celgene acquisition and the related debt restructuring is being managed with flexibility. The extension of the expiration date from November 6 to November 8, 2019, provides additional time for noteholders to participate in the offers and ensures alignment with the anticipated closing of the merger. The settlement of these offers is contingent upon the successful closing of the Celgene acquisition.
Key Highlights
- 1BMY extended the expiration date for its exchange offers and consent solicitations for Celgene notes to November 8, 2019.
- 2These offers are directly linked to Bristol-Myers Squibb's pending acquisition of Celgene.
- 3The exchange offers allow Celgene noteholders to swap their debt for new BMY notes and cash.
- 4The consent solicitations seek to amend the terms of Celgene's existing notes, removing restrictive covenants.
- 5The settlement of these offers is conditional upon the closing of the Celgene merger, a condition that cannot be waived.
- 6The Celgene acquisition is expected to be completed by the end of 2019.
- 7The company will provide notice of any further extensions to the expiration date.